Keywords: pfizer, fablyn, gets, nod, chmp, global, drug

Pfizer's Fablyn gets nod from CHMP

Article | 12 January 2009

Global drug giant Pfizer's drug Fablyn (lasofoxifene tartrate) has been recommended for approval for osteoporosis in women with increased risk ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Go to company listing